Literature DB >> 3011404

Identification of the human papilloma virus-1a E4 gene products.

J Doorbar, D Campbell, R J Grand, P H Gallimore.   

Abstract

Antibodies prepared against a human papilloma virus-1 (HPV-1) E4/beta-galactosidase fusion protein identified several polypeptides in HPV-1, but not HPV-2 or 4, induced papillomas. The major E4 protein, that represented up to 30% of total cellular protein, was a 16/17-K doublet which was purified by column chromatography and analysed for amino acid content. A peptide derived by chymotryptic digestion was purified by h.p.l.c. and subjected to amino acid sequencing. The unique sequence obtained, Gly-His-Pro-Asp-Leu-Ser-Leu, identified the 16/17-K doublet as a product of the HPV-1 E4 gene region. Antibodies to both the E4/beta-galactosidase fusion protein and the 16/17-K doublet identified two smaller polypeptides (10/11-K) which may represent spliced products of E4. We propose that the products of the HPV-1 E4 gene region are not classical DNA tumor virus early proteins and suggest that they play a role in virus maturation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011404      PMCID: PMC1166739          DOI: 10.1002/j.1460-2075.1986.tb04219.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  33 in total

1.  Quantitation of papova virus particles in human warts.

Authors:  J G BARRERA-ORO; K O SMITH; J L MELNICK
Journal:  J Natl Cancer Inst       Date:  1962-09       Impact factor: 13.506

2.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

3.  Characterization of proteins of human papilloma viruses (HPV) and antibody response to HPV 1.

Authors:  H Pfister; H zur Hausen
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

4.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

5.  Troponin C-like proteins (calmodulins) from mammalian smooth muscle and other tissues.

Authors:  R J Grand; S V Perry; R A Weeks
Journal:  Biochem J       Date:  1979-02-01       Impact factor: 3.857

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Human papilloma viruses (HPV): characterization of four different isolates.

Authors:  L Gissmann; H Pfister; H Zur Hausen
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

8.  Seroepidemiologic studies of bovine papillomavirus infections.

Authors:  H Pfister; B Huchthausen; G Gross; H zur Hausen
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

9.  Construction of plasmid cloning vehicles that promote gene expression from the bacteriophage lambda pL promoter.

Authors:  H U Bernard; E Remaut; M V Hershfield; H K Das; D R Helinski; C Yanofsky; N Franklin
Journal:  Gene       Date:  1979-01       Impact factor: 3.688

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  61 in total

1.  A cyclin-binding motif in human papillomavirus type 18 (HPV18) E1^E4 is necessary for association with CDK-cyclin complexes and G2/M cell cycle arrest of keratinocytes, but is not required for differentiation-dependent viral genome amplification or L1 capsid protein expression.

Authors:  Gillian L Knight; Alice G Pugh; Emma Yates; Ian Bell; Regina Wilson; Cary A Moody; Laimonis A Laimins; Sally Roberts
Journal:  Virology       Date:  2011-01-31       Impact factor: 3.616

2.  Modulation of the cell division cycle by human papillomavirus type 18 E4.

Authors:  Tomomi Nakahara; Akiko Nishimura; Masakazu Tanaka; Takaharu Ueno; Akinori Ishimoto; Hiroyuki Sakai
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Mutational analysis of the 3' open reading frames and the splice junction at nucleotide 3225 of bovine papillomavirus type 1.

Authors:  P L Hermonat; P M Howley
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Identification of the human papillomavirus E2 protein in genital tract tissues.

Authors:  C C Li; R V Gilden; S D Showalter; K V Shah
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Multiple cis-active elements in the long control region of bovine papillomavirus type 1 (BPV-1).

Authors:  S M Harrison; K L Gearing; S Y Kim; A J Kingsman; S M Kingsman
Journal:  Nucleic Acids Res       Date:  1987-12-23       Impact factor: 16.971

Review 6.  The molecular biology of human papillomaviruses and the pathogenesis of genital papillomas and neoplasms.

Authors:  R S Ostrow; A J Faras
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Role of the E1--E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31.

Authors:  Regina Wilson; Frauke Fehrmann; Laimonis A Laimins
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia.

Authors:  H A Cubie; M Norval; L Crawford; L Banks; T Crook
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

Review 9.  A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication.

Authors:  Christopher Netherton; Katy Moffat; Elizabeth Brooks; Thomas Wileman
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

10.  Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.

Authors:  J C Steele; T Stankovic; P H Gallimore
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.